Product Images Tresiba
View Photos of Packaging, Labels & Appearance
- Figure 1: Structural Formula of Tresiba - image 01
- Figure 2: Mean GIR profile for 0.4 U/kg dose of TRESIBA (steady state) in patients with Type 1 diabetes mellitus - image 02
- Figure A: NovoFine Needle Components - image 03
- Figure A: NovoTwist Needle Components - image 04
- Figure A: TRESIBA FlexTouch Pen Components - image 05
- Figure A: NovoFine Needle Components - image 06
- Figure A: NovoTwist Needle Components - image 07
- 100 U/mL IFU - Figure B - image 08
- 100 U/mL IFU - Figure C - image 09
- 100 U/mL IFU - Figure D - image 10
- 100 U/mL IFU - Figure E - image 11
- 100 U/mL IFU - Figure F - image 12
- 100 U/mL IFU - Figure G - image 13
- 100 U/mL IFU - Figure H - image 14
- 100 U/mL IFU - Figure I - image 15
- 100 U/mL IFU - Figure J - image 16
- 100 U/mL IFU - Figure K - image 17
- 100 U/mL IFU - Figure L - image 18
- 100 U/mL IFU - Figure M - image 19
- 100 U/mL IFU - Figure N - image 20
- 100 U/mL IFU - Figure O - image 21
- 100 U/mL IFU - Figure P - image 22
- 100 U/mL IFU - Figure Q - image 23
- 100 U/mL IFU - Figure R - image 24
- 100 U/mL IFU - Figure S - image 25
- 100 U/mL IFU - Figure T - image 26
- QR Code 100 units/mL - image 27
- Cover Page: Tresiba FlexTouch 100 units/mL - image 28
- Figure A: Tresiba FlexTouch U200 Pen Components - image 29
- 200 U/mL IFU Figure B - image 30
- 200 U/mL IFU Figure C - image 31
- 200 U/mL IFU Figure D - image 32
- 200 U/mL IFU Figure E - image 33
- 200 U/mL IFU Figure F - image 34
- 200 U/mL IFU Figure G - image 35
- 200 U/mL IFU Figure H - image 36
- 200 U/mL IFU Figure I - image 37
- 200 U/mL IFU Figure J - image 38
- 200 U/mL IFU Figure K - image 39
- 200 U/mL IFU Figure L - image 40
- 200 U/mL IFU Figure M - image 41
- 200 U/mL IFU Figure N - image 42
- 200 U/mL IFU Figure O - image 43
- 200 U/mL IFU Figure P - image 44
- 200 U/mL IFU Figure Q - image 45
- 200 U/mL IFU Figure R - image 46
- 200 U/mL IFU Figure S - image 47
- 200 U/mL IFU Figure T - image 48
- QR Code 200 units/mL IFU - image 49
- U-100 - image 50
- U-200 - image 51
- Figure 3 - image 52
- image 53
- image 54
- image 55
- image 56
- image 57
- image 58
- image 59
- image 60
- image 61
- image 62
- image 63
- image 64
- image 65
Product Label Images
The following 65 images provide visual information about the product associated with Tresiba NDC 0169-2550 by Novo Nordisk, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 2: Mean GIR profile for 0.4 U/kg dose of TRESIBA (steady state) in patients with Type 1 diabetes mellitus - image 02

100 U/mL IFU - Figure L - image 18

This seems to be a description of a FlexTouch insulin pen. It has a dose counter, dose selector button, dose pointer, and an insulin scale window. It appears to be for use with U-100 insulin only. There is also a "pen cap" included. The otherwise unclear text and characters suggest that this may be a medical device manual or packaging information.*
200 U/mL IFU Figure K - image 39

This text is describing insulin dosage options using a Pencap scale window and a selector. It appears to be a partial list of features or instructions related to an insulin administration system.*
200 U/mL IFU Figure L - image 40

The text describes the packaging or components of a medical device called "NovoFine". It mentions an outer needle cap and an inner needle cap, without providing additional specifics. The letters "L" and "ey o" are also present, but their significance is unclear.*
200 U/mL IFU Figure N - image 42

TRESIBA is an injection of insulin degludec used to control high blood sugar levels in people with diabetes.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.